Ascletis Pharma Inc. (OTCMKTS:ASCLF) Sees Significant Increase in Short Interest

Ascletis Pharma Inc. (OTCMKTS:ASCLF) was the recipient of a large growth in short interest in January. As of January 30th, there was short interest totaling 593,545 shares, a growth of 30.0% from the January 15th total of 456,545 shares. Based on an average daily volume of 3,532 shares, the short-interest ratio is presently 168.0 days. Based on an average daily volume of 3,532 shares, the short-interest ratio is presently 168.0 days.

Ascletis Pharma Stock Performance

Shares of ASCLF opened at $2.10 on Monday. The company has a 50-day simple moving average of $1.76 and a two-hundred day simple moving average of $1.59. Ascletis Pharma has a one year low of $0.62 and a one year high of $2.29.

About Ascletis Pharma

Ascletis Pharma (OTCMKTS:ASCLF) is a clinical‐stage biopharmaceutical company headquartered in Hangzhou, China, dedicated to the research, development and commercialization of therapies for viral and liver diseases. Since its founding in 2013, the company has built an integrated platform spanning small‐molecule discovery, process chemistry and clinical development. Ascletis is listed on the Hong Kong Stock Exchange and maintains facilities for both clinical research and commercial manufacturing in Mainland China.

The company’s core pipeline focuses on direct‐acting antiviral agents targeting hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).